GTBP

GT Biopharma, Inc. (GTBP) - 2025 Annual Report Summary

Business Context and Reporting Period

Company: GT Biopharma, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: GT Biopharma is a clinical-stage biopharmaceutical company developing immuno-oncology products using its proprietary Tri-specific Killer Engager (TriKE®) and Dual Targeting TriKE® platforms. These therapies harness natural killer (NK) cells to target cancer cells. The company operates as a single segment and became fully remote effective July 1, 2024.

Key Financial Metrics (Year Ended Dec 31, 2025)

Note: The 2025 Net Loss includes a non-cash loss of $28.7 million on the initial recognition of "Greenshoe Rights" liability and a $11.4 million gain on the change in fair value of that liability, followed by a reclassification to equity in September 2025.

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by approximately $15.2 million (115%) primarily due to the accounting treatment of the Greenshoe Rights liability associated with the Series L Preferred Stock issuance in May 2025. This was partially offset by a decrease in R&D expenses.
• R&D Expense Decrease: R&D expenses decreased by $2.3 million (40%) due to reduced production and materials costs, despite advancing clinical trials.
• Liquidity Improvement: Working capital improved from a deficit of $1.7 million in 2024 to a positive $5.8 million in 2025, driven by financing activities including the issuance of Series L Preferred Stock and warrant exercises.
• Restatement: The company restated its interim financial statements for Q2 and Q3 2025 to correct the classification of Greenshoe Rights from equity to liability, resulting in a material weakness in internal controls.

Guidance, Outlook, Risks, and Unusual Items

Going Concern: The company's independent auditors have raised substantial doubt about its ability to continue as a going concern. Management believes existing cash resources ($6.9 million) are insufficient to fund operations for one year from the filing date without additional financing.

Clinical Pipeline Progress:

• GTB-3650: Phase 1 trial for relapsed/refractory AML and high-risk MDS began enrollment in January 2025.
• GTB-5550: IND cleared in January 2026; Phase 1 basket trial for solid tumors expected to initiate mid-2026.
• GTB-3550: Development suspended to focus on second-generation camelid nanobody TriKEs.

Unusual Items:

• Greenshoe Rights: A significant non-cash accounting event involving the Series L Preferred Stock issuance. The liability was initially recognized at $28.7 million and later reclassified to equity upon waiver of redemption rights in September 2025.
• Vendor Settlement: Recognized a $1.0 million gain on the settlement of a vendor payable in June 2025.

Risks:

• Capital Needs: Uncertainty regarding the ability to secure additional funding on acceptable terms.
• Nasdaq Compliance: Received notice in November 2025 of non-compliance with the $1.00 minimum bid price requirement. The company has until May 19, 2026, to regain compliance or face delisting.
• Internal Controls: Identified a material weakness in internal control over financial reporting related to the accounting for complex financial transactions (Greenshoe Rights).

Investor Verification Checklist

• Capital Runway: Verify the company's ability to raise additional capital given the "substantial doubt" going concern opinion and current cash balance of ~$6.9 million.
• Nasdaq Status: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement by May 19, 2026, to avoid delisting.
• Restatement Impact: Review the restated Q2 and Q3 2025 financials to understand the full impact of the Greenshoe Rights accounting correction on historical performance.
• Clinical Milestones: Track enrollment and data readouts for the GTB-3650 (AML/MDS) and GTB-5550 (Solid Tumors) trials, which are critical for future valuation.
• Internal Controls: Assess the remediation plan for the material weakness in internal controls to ensure future financial reporting reliability.